Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Lees

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesKamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Journal of Medicinal Chemistry|October 22, 2024
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) KinaseJennifer X Qiao, David Williams, Patrice Gill, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation PathwayJames J Mignone, Elizabeth A Jurica, Deepa Rajasekaran, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Cancer Discovery|May 21, 2017
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal CancersCarl U Bialucha, Scott D Collins, Xiao Li, et al.
Nature Communications|January 31, 2026
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12CMatthew L Condakes, Zhuo Zhang, Derek B Danahy, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesKamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Journal of Medicinal Chemistry|October 22, 2024
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) KinaseJennifer X Qiao, David Williams, Patrice Gill, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation PathwayJames J Mignone, Elizabeth A Jurica, Deepa Rajasekaran, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Cancer Discovery|May 21, 2017
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal CancersCarl U Bialucha, Scott D Collins, Xiao Li, et al.
Nature Communications|January 31, 2026
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12CMatthew L Condakes, Zhuo Zhang, Derek B Danahy, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 4